Back to News
Oct 8, 2025 12:00 PM

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE).

The patients had unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), positive somatostatin analog imaging, and at least one site of measurable disease.

The study showed AlphaMedix (212Pb-DOTAMTATE) met all primary efficacy endpoints.

AlphaMedix is an investigational somatostatin receptor (SSTR)-Targeted Alpha Therapy using the lead-212 isotope.

It showed clinically meaningful overall response rates (ORR) and prolonged clinical benefits in ...